|Dr. Zhengbin Yao||Chairman, Pres & CEO||N/A||N/A||1966|
|Mr. Mitchell Chan||Chief Financial Officer||N/A||N/A||1981|
|Dr. Aaron Ren M.B.A., Ph.D.||VP and Head of Bus. Devel. & Operations||N/A||N/A||1977|
|Ms. Kate Surdez||VP & Head of HR||N/A||N/A||N/A|
|Dr. Jörn Drappa M.D., Ph.D.||Chief Medical Officer and Head of R&D||N/A||N/A||1964|
Viela Bio, Inc., a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company is developing inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder; kidney transplant desensitization; myasthenia gravis; and IgG4-related diseases. It is also developing VIB4920 for kidney transplantation rejection and sjögren's syndrome; and VIB7734 for cutaneous lupus erythematosus. The company has a strategic collaboration with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases in Japan and Other Asia Regions. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.
Viela Bio, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.